DexCom (DXCM) Stock Price, News & Analysis

Company Overview

DexCom, Inc. develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its devices use a small wearable sensor to measure glucose levels in real time and transmit readings to compatible smartphones, receivers, smartwatches, and other connected devices, helping users monitor glucose trends and make informed decisions about their health.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 CGM systems, as well as Dexcom ONE and Dexcom ONE+ products offered in select markets. DexCom also provides digital tools and services, including the Dexcom Clarity platform for glucose data analysis and Dexcom Follow for sharing glucose information with caregivers and healthcare professionals. Stelo, an over-the-counter glucose biosensor, expands the company’s offerings to certain adults who do not use insulin.

Founded in 1999 and headquartered in San Diego, California, DexCom serves customers in the United States and international markets. Its products are used by people with Type 1 and Type 2 diabetes, healthcare providers, caregivers, and, in applicable markets, adults seeking information about their glucose patterns.

Key Stats

• Today's Range: $85.14 to $87.08
• 50-Day Range: $83.03 to $92.34
• 52-Week Range: $54.11 to $92.59
• Volume: 2.39 million shs
• Average Volume: 3.40 million shs
• Market Capitalization: $32.35 billion
• P/E Ratio: 33.72
• Dividend Yield: N/A
• Price Target: $92.43
• Consensus Rating: Buy

DexCom Stock Analysis - MarketRank™

DexCom scored higher than 92% of companies evaluated by MarketBeat, and ranked 24th out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Buy

Consensus Rating

DexCom has received a consensus rating of Buy. The company's average rating score is 3.04, and is based on 3 strong buy ratings, 19 buy ratings, 2 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for DexCom is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

DexCom has been the subject of 17 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 16.67%

Earnings Growth

Earnings for DexCom are expected to grow by 16.67% in the coming year, from $2.64 to $3.08 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of DexCom is 33.72, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.77.

Price to Earnings Ratio vs. Sector

The P/E ratio of DexCom is 33.72, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 195.56.

Price to Earnings Growth Ratio

DexCom has a PEG Ratio of 1.44. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

DexCom has a P/B Ratio of 12.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.73% of the float of DexCom has been sold short.

Short Interest Ratio / Days to Cover

DexCom has a short interest ratio ("days to cover") of 3.16, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in DexCom has recently decreased by 18.80%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

DexCom does not currently pay a dividend.

Dividend Growth

DexCom does not have a long track record of dividend growth.

News and Social Media

• Score: 4.2 / 5
• News Sentiment: 0.72

News Sentiment

DexCom has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for DexCom this week, compared to 9 articles on an average week.

Search Interest

13 people have searched for DXCM on MarketBeat in the last 30 days. This is an increase of 225% compared to the previous 30 days.

MarketBeat Follows

5 people have added DexCom to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, DexCom insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,091,191.00 in company stock.

Percentage Held by Insiders

0.28% of the stock of DexCom is held by insiders.

Percentage Held by Institutions

97.75% of the stock of DexCom is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/20/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:DXCM
• CIK: 1093557
• Web: www.dexcom.com
• Phone: (858) 200-0200
• Fax: 858-200-0201
• Employees: 11,000
• Year Founded: 1999

Price Target and Rating

• Average Price Target for DexCom: $92.43
• High Price Target: $115.00
• Low Price Target: $75.00
• Potential Upside/Downside: +7.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.04
• Research Coverage: 24 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.53
• Trailing P/E Ratio: 33.72
• Forward P/E Ratio: 32.48
• P/E Growth: 1.44
• Net Income: $836.30 million
• Net Margins: 20.12%
• Pretax Margin: 25.76%
• Return on Equity: 35.94%
• Return on Assets: 14.75%

Debt

• Debt-to-Equity Ratio: 0.47
• Current Ratio: 1.73
• Quick Ratio: 1.43

Sales & Book Value

• Annual Sales: $4.66 billion
• Price / Sales: 6.94
• Cash Flow: $2.76 per share
• Price / Cash Flow: 31.05
• Book Value: $7.04 per share
• Price / Book: 12.18

Miscellaneous

• Outstanding Shares: 377,360,000
• Free Float: 376,304,000
• Market Cap: $32.35 billion
• Optionable: Optionable
• Beta: 1.48